Navigation Links
Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
Date:1/3/2009

now acquire higher predictive value and greater specificity from a complex biological system such as the regulation of the estrogen receptor pathways. I believe this puts Bionovo at the forefront of future SERM products which are far more specific and a more favorable safety profile. This is a breakthrough for all future drugs that regulate the vast diverse effects of conditions affected by nuclear receptors. Bionovo is positioned to explore and exploit these pathways for many serious diseases with its expanded scientific collaborations. We are proud to continue pursuing our innovative approaches to drug discovery and development in these challenging times."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, effic
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Distinguished Professor of Engineering at the University of ... solve problems in energy engineering, environmental sustainability and ... zeolites, porous rock with a well-defined, crystalline structure. ... so precisely decided that zeolites can separate molecules ... an angstrom (one-tenth of a nanometer), making them ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... , MURRIETA, Calif., Aug. 27 Despite ... of its US operations. Copan Diagnostics, Inc. is undertaking a ... and additional medical device manufacturing operations to its facility in ... molding machinery and filling and packing equipment to expand Copan,s ...
... , GAITHERSBURG, Md., Aug. 27 GenVec, ... into a purchase agreement with a single institutional investor for the sale ... shares of its common stock. The shares of common stock and ... stock and 0.50 warrants to purchase one share of common stock at ...
... Elbit Imaging Ltd.,("EMI" or the "Company") (NASDAQ: EMITF ... the Page" of Series B Notes of the Company,that the interest ... August 21, 2009 and ending on February 20, 2010 is 1.723125%. ... The Activities of Elbit Imaging Ltd. are divided ...
Cached Biology Technology:Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes 2Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes 3
(Date:7/25/2014)... in the International Journal of Cancer earlier ... cancer based on findings showing successful reduction in the ... population of cells in the cervix. , The ... junction cells, or SCJ cells. These cells reside in ... origins of cervical cancer. A research team co-led by ...
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
(Date:7/25/2014)... at the University of Houston, has written a ... development., "Introduction to Tissue Engineering: Applications and Challenges" ... field of artificial organ development. Metin Akay, founding ... served as a series editor on the book., ... books on the subject of growing artificial organs ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2University of Houston researcher publishes textbook on tissue engineering 2
... , During heavy rain, the lid of Nepenthes ... that seek shelter on its underside directly into the ... published today, Wednesday 13 June, in the journal ... insects as a source of nutrients, enabling them to ...
... unfathomable only a few years ago are reality today ... the acquisition of next-generation sequencing technology on the Texas ... of the service. "As we move into the ... in history," said Dr. Charles Johnson, director of the ...
... wide range of diseases and uncover fundamental processes that lead ... for biomedical science. A number of hurdles, both scientific and ... of using these special cells to treat heart disease, diabetes, ... June 13 in Nature , scientists at the Salk ...
Cached Biology News:Pitcher plant uses rain drops to capture prey 2Next-generation sequencing technology opens doors to discoveries 2'Magical state' of embryonic stem cells may help overcome hurdles to therapeutics 2'Magical state' of embryonic stem cells may help overcome hurdles to therapeutics 3
BOND ELUT MATRIX-C18, 25 mg ...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human Legumain Affinity Purified Polyclonal Ab...
Biology Products: